Oculis
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- -
- Employees
- 36
- Market Cap
- $553.1M
- Introduction
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
Oculis reports progress in OCS-01 DIAMOND Phase 3 DME and OCS-05 Phase 2 AON trials, with topline readout expected in December 2024. The company bolsters its leadership team and maintains a $125.0 million cash runway into 2H 2026.
Oculis Holding AG announces enrollment acceleration for Phase 3 DIAMOND trials for eye
Oculis Holding AG accelerates patient enrollment in DIAMOND-1 and DIAMOND-2 Phase 3 trials for OCS-01 eye drops, a non-invasive treatment for diabetic macular edema (DME). The trials show promising results in visual acuity and macular edema reduction, with substantial enrollment progress reported. Oculis expands its DIAMOND program committees with global retina experts to support OCS-01 development.
Oculis Accelerates Enrollment in both DIAMOND Phase 3
Oculis announces acceleration of patient enrollment for Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME) and expansion of the DIAMOND program committees with globally renowned retina experts. OCS-01 has the potential to transform DME treatment as the first topical eye drop therapy.
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic
Oculis announces accelerated enrollment in Phase 3 DIAMOND trials for OCS-01 eye drops in DME, with ~70% and ~40% of patients enrolled in DIAMOND-1 and DIAMOND-2, respectively. The DIAMOND program committees, now expanded with globally renowned retina experts, aim to evaluate OCS-01's efficacy and safety as a potential first topical treatment for DME.
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Oculis accelerates enrollment in DIAMOND Phase 3 trials of OCS-01 for diabetic macular edema, with DIAMOND-1 at ~70% and DIAMOND-2 at ~40%. The company expands DIAMOND program committees with retina experts. OCS-01 could be the first topical eye drop for DME, transforming treatment.
© Copyright 2025. All Rights Reserved by MedPath